13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
|
SANOFI SA INHABER EO 2 |
920657 |
Xetra |
88,900 |
24.06.24 10:37:04 |
+1,510 |
+1,73% |
88,950 |
89,010 |
87,820 |
87,390 |
|
REGENERON PHARMAC.DL-,001 |
881535 |
Frankfurt |
984,600 |
24.06.24 08:12:32 |
-3,000 |
-0,30% |
979,200 |
989,000 |
984,600 |
987,600 |